David D. Chang, President and CEO of Allogene Therapeutics, Inc. ($ALLO), sold shares on the open market twice in the last year, totaling about $263,000. His most recent sale occurred on February 2, 2026. These sales rank 7,849th among 11,678 individual insiders, far below the average of $8.6 million per seller and 6.4 transactions. Chang made no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 16, 2026 | Allogene Therapeutics, Inc. | $ALLO | Chang David D | President and CEO | S | Common Stock | 47763 | $2.47 | 8,063,795.0000 | 224,730,144 | 0.59% | 0.02% |
| Feb. 2, 2026 | Allogene Therapeutics, Inc. | $ALLO | Chang David D | President and CEO | A | Restricted Stock Unit | 392586 | $0.00 | 392,586.0000 | 224,730,144 | 9999.99% | 0.17% |
| Feb. 2, 2026 | Allogene Therapeutics, Inc. | $ALLO | Chang David D | President and CEO | A | Stock Option (Right to buy) | 1387931 | $0.00 | 1,387,931.0000 | 224,730,144 | 9999.99% | 0.62% |
| Feb. 2, 2026 | Allogene Therapeutics, Inc. | $ALLO | Chang David D | President and CEO | S | Common Stock | 95269 | $1.80 | 8,099,058.0000 | 224,730,144 | 1.16% | 0.04% |
| March 14, 2025 | Allogene Therapeutics, Inc. | $ALLO | Chang David D | President and CEO | S | Common Stock | 46668 | $1.96 | 8,189,765.0000 | 217,264,738 | 0.57% | 0.02% |
| Feb. 3, 2025 | Allogene Therapeutics, Inc. | $ALLO | Chang David D | President and CEO | S | Common Stock | 46003 | $1.68 | 8,230,433.0000 | 0 | 0.56% | 0.00% |
| Jan. 24, 2025 | Allogene Therapeutics, Inc. | $ALLO | Chang David D | President and CEO | A | Stock Option (Right to buy) | 1952130 | $0.00 | 1,952,130.0000 | 0 | 9999.99% | 0.00% |
| Jan. 24, 2025 | Allogene Therapeutics, Inc. | $ALLO | Chang David D | President and CEO | A | Common Stock | 552174 | $0.00 | 8,276,436.0000 | 0 | 7.15% | 0.00% |
| May 16, 2024 | Allogene Therapeutics, Inc. | $ALLO | Chang David D | President and CEO | A | Common Stock | 344828 | $2.90 | 7,723,302.0000 | 0 | 4.67% | 0.00% |
| March 14, 2024 | Allogene Therapeutics, Inc. | $ALLO | Chang David D | President and CEO | F | Common Stock | 53393 | $4.33 | 7,378,474.0000 | 0 | 0.72% | 0.00% |
| Jan. 25, 2024 | Allogene Therapeutics, Inc. | $ALLO | Chang David D | President and CEO | A | Stock Option (Right to buy) | 1123535 | $0.00 | 1,123,535.0000 | 0 | 9999.99% | 0.00% |
| Jan. 25, 2024 | Allogene Therapeutics, Inc. | $ALLO | Chang David D | President and CEO | A | Common Stock | 317800 | $0.00 | 7,426,399.0000 | 0 | 4.47% | 0.00% |
| March 22, 2023 | Allogene Therapeutics, Inc. | $ALLO | Chang David D | President and CEO | A | Stock Option (Right to Buy) | 1492200 | $0.00 | 1,492,200.0000 | 0 | 9999.99% | 0.00% |
| March 22, 2023 | Allogene Therapeutics, Inc. | $ALLO | Chang David D | President and CEO | A | Common Stock | 1924464 | $0.00 | 7,107,107.0000 | 0 | 37.13% | 0.00% |
| March 14, 2023 | Allogene Therapeutics, Inc. | $ALLO | Chang David D | President and CEO | F | Common Stock | 22340 | $5.56 | 5,182,643.0000 | 0 | 0.43% | 0.00% |